Werewolf Therapeutics

Drug development oncology


HBM contact: Dr Ivo Staijen, Dr Michael Buschle

Company status: public

Cytokine treatment of certain forms of cancer has led in some instances to impressive clinical responses. However, therapies with such immunomodulating compounds are frequently not tolerated and can lead to severe, life-threatening side effects, limiting their use in oncology. 
To avoid side effects and to achieve full clinical efficacy, Werewolf are developing a number of Indukines. These are proprietary, conditionally-activated immunomodulating molecules that are only active at the site of a tumor, thus sparing normal tissue. In addition, these molecules have improved pharmacological properties.

© HBM Partners AG  |  Bundesplatz 1  |  6300 Zug, Switzerland  |  Phone  +41 43 888 7171